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Summary In order to assess the role of maintenance melphalan and prednisone (MP) in responding multiple
myeloma patients, 185 eligible patients who responded to initial MP with stabilization for at least 4 months
were randomized to either stop treatment and resume therapy at relapse or to continue MP until relapse.
Time to first relapse was significantly shorter in the no maintenance group (P=0.0011), however 57% of the
no maintenance patients had a second response when MP was restarted and others had minor improvement.
The time to final progression on MP, which reflects the duration of disease control by MP, was therefore
longer for the no maintenance group (median=39 months) compared to the maintenance group (median=31
months) although the observed difference was not statistically significant (P=0.086). Median survival from
start of MP in the maintenance group (46 months) was also not significantly different than the no
maintenance group (51 months) (P=0.587). Multifactor analysis of the randomized patients demonstrated
shorter total remission duration and shorter survival in patients who had an initially rapid response to
therapy or a lesser reduction in serum M-protein concentration.
A high percentage of multiple myeloma patients will respond
to melphalan and prednisone (MP) therapy and response
duration is frequently quite long (Alexanian et al., 1969;
Bergsagel et al., 1979). Consequently, the duration of
therapy in responding patients is often measured in years.
However, prolonged treatment is not without toxicity and
the potential for an increased risk of leukaemia with
prolonged melphalan therapy is of particular concern.
Consequently, the need to continue treatment until
progression in patients who have had a stable response has
been questioned. The Southwest Oncology Group (SWOG)
addressed this question in a randomized trial comparing no
maintenance therapy to either continuing MP or carmustine
plus prednisone in patients who had responded and
remained in remission for at least 12 months after starting
treatment with an MP induction regimen (Southwest
Oncology Group Study, 1975; Alexanian et al., 1978). No
differences were detected either in survival or time to relapse
but the sample size was small with only 28 patients
randomized to the no maintenance arm and so the power of
the study to detect a clinically significant difference was low.
The British Medical Research Council also examined this
question in their Myelomatosis Trial (Medical Research
Council Working Party on Leukaemia in Adults, 1985).
Myeloma patients were randomized to receive oral
melphalan plus prednisone, with or without intravenous
vincristine. Patients who had maintained a constant
paraprotein level and a stable urinary light chain excretion
for at least six months, along with a stable haematological
and clinical condition, were randomized to either stopping
treatment until relapse or continuing initial chemotherapy
for another year. A total of 226 patients were randomized in
this second randomization of maintenance for one year
versus no maintenance therapy. The no maintenance group
had a slightly superior survival experience but the observed
difference was not statistically significant.
In 1977, the Clinical Trials Group of the National Cancer
Institute of Canada (NCIC) initiated a similar trial to assess
the role of maintenance therapy for responding multiple
myeloma patients. All eligible myeloma patients received MP
as induction therapy. Those who achieved a stable response
were randomized to receive maintenance MP until relapse, or
no further treatment until relapse. Patients who relapsed on
the no maintenance therapy arm were retreated with MP.
The study was also designed to see if the no maintenance
group actually received a significantly lower total dose of
melphalan and, if so, did this result in a lower incidence of
acute leukaemia. The response rate to restarting MP at
relapse in the unmaintained arm and prognostic factors
predictive of a second response were also assessed.
Patients and methods
Patients were eligible for the trial if they had histologic
confirmation of multiple myeloma consisting either of
> 10% plasma cells in the bone marrow or biopsy of a bone
or soft tissue lesion showing malignant plasma cell pro-
liferation. Patients must have had no prior chemotherapy
and they had to have a measurable serum or urinary
M-protein. Patients with other serious concurrent illness
unrelated to their myeloma were excluded. After explanation
of the study, informed consent was obtained from all
patients according to local institutional guidelines.
Initial treatment consisted of melphalan 9mgm-2 orally
daily for 4 days and prednisone 100mg daily for 4 days; this
cycle was repeated every 28 days. The dose of melphalan was
increased to 12 mgm-2 if the granulocyte nadir was not less
than 0.5 x 1091-1. If the patient did not respond with a fall
in the M-protein, subsequent courses of melphalan were
increased until clear evidence of haematological toxicity,
indicating adequate absorption of melphalan, was observed.
Melphalan was reduced to 75% of the previous dose if the
granulocyte nadir was less than 0.5 x 109 -1. If the
treatment day white blood cell count was less than
2.0 x 100 1 1 or the platelet count less than 50 x 109 1-1,
treatment was delayed until counts were above these levels.
Treatment was then resumed at 75% of the previous dose.
Radiation therapy was used as indicated for the treatment of
painful osteolytic lesions and spinal cord compression.
Supportive care for pain, infections, anaemia and hyper-
calcemia were also given.
Response was monitored by monthly serum electro-
phoresis, 24-h urine protein analysis and monthly blood
chemistries. Complete skeletal X-rays were done every 6
months with site specific X-rays taken whenever clinically
indicated.
Response was defined as a decrease to less than 50% of
the baseline serum M-protein concentration and a decrease
of over 90% of baseline light chain 24-h proteinuria on two
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successive monthly determinations. However, patients were
not eligible for randomization unless they not only
responded but also had their serum and urine M-protein
remain below the response level without fluctuation about
the mean of more than + 10% for at least 4 consecutive
months during continued treatment. If they fulfilled these
criteria and consented to randomization, they were
randomized. Randomization took place by telephone contact
with the central office of the Clinical Trials Group of the
National Cancer Institute of Canada in Kingston, Ontario.
Stratification was by participating institution only.
Patients on both study arms continued to have regular
monthly follow-up with clinical and laboratory assessment.
Patients randomized to maintenance therapy continued on
monthly MP until relapse, defined as one or more of the
following:
(a) a minimum rise in serum M-protein of 10g 1 above
the nadir,
(b) a minimum increase in urinary M-protein of 2.0 g
24h-1,
(c) reappearance of light chain proteinuria or reappearance
of a serum M-protein,
(d) increase in size or number of lytic bone lesions,
(e) the development of hypercalcemia.
In the no maintenance arm, MP was discontinued and
reinstituted upon relapse. A response to resumption of
therapy at relapse was defined as a reduction in serum M-
protein or urine M-protein to at least the nadir value of the
first response for at least two measurements taken 1 month
apart. It is important to note that patients were not required
to have symptoms of relapse at the time of reinstitution of
therapy. Once a second stable response was achieved, MP
was again stopped and not restarted until a second relapse
occurred.
Serial serum M-protein values were plotted against time
on semilogarithmic graph paper for individual patients. For
responding patients, the fall in serum M-protein was usually
exponential and the time required for the value to fall to
50% of the initial value was measured as the T 1/2 serum
M-protein. The percent fall in serum M-protein was
calculated by dividing the value of the serum M-protein at
the response plateau by the pre-treatment value and
multiplying by 100. We were unable to measure the T 1/2 or
percent fall in M-protein for patients producing only light
chains, since unmeasured catabolism of light chains by the
kidney (Wochner et al., 1967) can have a significant effect on
these values. In relapsing patients, the time required for the
serum M-protein to double in quantity was determined by
the above-mentioned plot of the serum M-protein values
against time. This is referred to as the doubling time. The
staging system used in this trial is that of Durie and Salmon
(Durie & Salmon, 1975).
Patient data were collected by the NCIC central office and
accuracy was confirmed by obtaining copies of all serum and
urine electrophoretic strips. Centralized reference immuno-
globulin typing and confirmation of the initial baseline value
was done by Dr W. Pruzanski at the University of Toronto
Immunology Diagnostic and Research Centre, Wellesley
Hospital, Toronto. All survival curves were determined using
the Kaplan-Meier technique (Kaplan & Meier, 1958) and
calculated from the time of starting MP. The statistical
significance of the difference between survival curves was
calculated using the log rank statistic. The statistical
significance of the prognostic factors, adjusted treatment
comparisons and treatment by prognostic factor interactions
were determined in a multifactor analysis using Cox's
proportional hazards models as provided by the procedure
PHGLM in the software package Statistical Analysis System
(SAS) (Sas Supplemental Library Users Guide, 1980).
Logistic regresion as provided by the procedure FUNCAT in
the software package SAS (Sas Supplemental Library Users
Guide, 1980) was used to determine the statistical
significance of the effect of prognostic variables on the
incidence of a second response to the resumption of MP in
the unmaintained arm. In the analysis the following variables
were entered as continuous: age, performance status,
haemoglobin, BUN, calcium, T 1/2 and percentage drop in
serum M-protein. No interim analyses were performed.
Results
Between January 1977 and March 1984, 530 patients were
registered from 21 Canadian cancer treatment centres.
Thirty-three patients were considered ineligible for the
following reasons: 14 patients had less than 10% plasma
cells in the bone marrow, 10 had no measurable M-protein,
5 were registered but did not start treatment, 3 had received
prior treatment with an alkylating agent and 1 had
concurrent prostatic carcinoma. Of the 497 eligible patients,
none of whom are lost to follow-up, 15 are not yet evaluable
for response to induction chemotherapy, and 25 are
inevaluable for response (15 died of causes unrelated to
myeloma before response could be assessed, and 10 refused
to continue treatment or had treatment stopped by their
physician before response could be assessed), leaving a total
of 457 evaluable patients. Two hundred and forty-seven of
these patients had either no change in their disease status on
MP, a response that did not last long enough to be eligible
for randomization, or progression of disease. Two hundred
and ten (46%) patients achieved a response that was stable
for at least 4 months, and were therefore eligible for
randomization. Twenty-five stabilized patients declined
randomization leaving 185 randomized patients. These
patients form the basis of this report and all randomized
patients are included in the analysis.
The distribution of known prognostic factors for the two
randomized groups and the group of responders who were
not randomized is shown in Table I. There were no
statistically significant differences in the distribution of sex,
age, initial performance status, haemoglobin, calcium, BUN,
pattern of bone involvement, type or quantity of monoclonal
protein or stage between these groups.
The median time to achieve a drop in serum M-protein of
50% or urine M-protein of 90% was identical in both study
groups at 89 days. The median time from starting therapy to
the time of randomization was 10.1 months in the main-
tenance group and 10.2 months in the no maintenance
group. The overall median duration of follow-up from the
initiation of MP is 49.4 months with a median duration of
follow-up of 36.7 months from the date of randomization.
The average total dose of melphalan in the maintenance
Table I Patient characteristics
Not No
randomized Maintenance maintenance
n 25 93 92
Median age 62 63 61
% Male 52 53 56
% Performance status>50' 60 74 78
% Hg<8.5gdl-1 16 8 9
% BUN>30mgdl-1 32 22 17
% Calcium> 12mgdl 1 12 12 6
% IgG 60 55 58
% IgA 24 28 28
% IgD 0 1 2
% K only 8 10 5
% L only 8 6 7
% Stage I 8 4 5
% Stage II 28 27 36
% Stage III 64 69 59
aKarnofsky scale.96 A. BELCH et al.
group is 1,310mg and 898 mg in the no maintenance group,
producing a substantial difference of 412 mg.
Figure 1 illustrates the time to first progression from the
start of treatment in the two study groups. These survival
curves are significantly different (P=0.0011, one-sided) with
the median time to progression in the maintained group
being 31 months compared to 23 months in the no main-
tenance group. However, it must be remembered that when
no maintenance patients relapse, 36 of 63 (57%) achieved a
second response with reinstitution of therapy, and seven
patients achieved a third response to further resumption of
MP (Table II). Some other patients had minor improvement
that did not fulfil the criteria of response. Consequently, the
duration of the reinduced remissions in the no maintenance
arm is clearly important. In order to summarize the influence
of subsequent treatment and response in the no maintenance
arm, we measured the interval from initiating MP to the
time that disease progression occurred despite melphalan
therapy (melphalan failure) for both arms. When the time to
eventual melphalan failure is examined in this fashion,
Figure 2 illustrates that the no maintenance group was now
slightly superior but not significantly so (P=0.086, two-
sided).
The failure of maintenance therapy to improve survival is
illustrated in Figure 3. There is no statistical difference
between these survival curves (P=0.5879, two-sided). The
upper 95% confidence limit of the ratio of median survival
of the maintenance group to the median survival of the no
maintenance group is 1.18 after adjusting for the significant
factors of age, percent change in serum M-protein, serum
calcium and time to 50% reduction of the serum M-protein.
Consequently we can reject, with less than 5% error, that
maintenance therapy increases median survival by more than
10.
0.9
Table II Second responses to melphalan and
prednisone for relapses on the no maintenance
arm
Number of relapses 79
Number restarted on M+P 66
Number evaluable for response 63
Number of responders 36 (57%)
18%. We conclude therefore that maintenance MP does not
significantly improve survival in multiple myeloma patients
who respond with stabilization to this treatment.
An analysis of known prognostic factors was done in
order to identify treatment interactions which might
distinguish which patients were at higher risk of early relapse
and to predict which patients should receive maintenance
therapy in future practice. A multifactor analysis of time to
first progression using proportional hazards models (Table
III) demonstrated that, although stage is not a significant
predictor, those patients with a shorter time to a 50%
reduction in their serum M-protein or a smaller reduction in
their serum M-protein had a shorter time to first progression
and a shorter time to eventual melphalan failure, irrespective
of whether they were receiving maintenance or no
maintenance therapy. Such patients are at a higher risk of
relapse regardless of whether they are receiving maintenance
therapy or not. In contrast, hypercalcemia at presentation
was a significant predictor of early relapse in the no
maintenance arm (P=0.001) but not in the maintenance arm
(P=0.23). In a multifactor proportional hazards analysis of
the effect of prognostic factors on survival, these same
factors were found to be important. Table IV illustrates that
older patients, those who presented with hypercalcemia,
those who responded with shorter serum M-protein halving
times, and those who achieved a smaller drop in serum
M-protein had a shorter survival. In this analysis, although
stage was significant as a single factor, it lost its significance
































12 24 36 48 60 72
Months from starting M + P
Figure 1 Duration of first remission. Open circles represent 92
patients on no maintenance therapy and closed circles represent
93 patients who received maintenance therapy. The median
duration of remission was 23 months and 31 months respectively,
P (l-sided)=0.001 1.
12 24 35 48 60 72
Monthsfrom starting M + P
Figure 2 Time to melphalan failure. Open circles represent 92
patients on no maintenance therapy and closed circles represent
93 patients who received maintenance therapy. The median
duration until eventual melphalan failure was 39 months and 31
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appears that for both duration of remission as well as for
survival, the pattern of response to the initial treatment
(usually evaluable within a few months of therapy) is a
major determining factor.
A possible explanation for the correlation between T 1/2
and survival is related to the serum M-protein doubling time
(DT) measured at relapse. When the initial T 1/2 was
compared to the doubling time (Table V) the Spearman
correlation coefficient was 0.28 (P=0.0141), indicating that
patients who responded with a rapid T 1/2 also relapsed
with a more rapid doubling time.
Sixteen of the 497 eligible patients have developed acute
nonlymphocytic leukaemia. This complication developed in 8
patients who were not randomized, in 5 who were
randomized to the maintenance arm and in 3 who were
randomized to the no maintenance arm. Consequently, at
this point, no significant difference in the incidence of
leukaemia in the two arms has been observed.
Of the 92 patients randomized to no maintenance therapy,
79 have relapsed and 66 have resumed MP. The remaining 13
eligible cases did not resume this therapy because of patient
refusal (1), pancytopenia (3) or opinion of their physician
(9). Of the 66 evaluable patients, 3 have not been followed
long enough to be evaluable for response.
The resumption of MP in these 63 relapsing patients
resulted in 36 (57%) second responses. The influence of
specific disease features at initial presentation on achieve-
ment of a second response is shown in Table VI. Single
factor logistic regression was used to assess the effect of first
remission duration, extent of initial drop in serum M-
protein, T 1/2 and the presence of symptoms at relapse on
the chance of achieving a second remission (Table VII).
Second responders had a longer first remission duration
(P=0.21, two-sided) and a significantly greater percentage
drop in initial serum M-protein (P=0.004, two-sided). A
cross tabulation of second response by whether or not the






Months from starting M + P
Figure 3 Survival of randomized responders. Open circles
represent 92 patients on no maintenance therapy and closed
circles represent 93 patients who received maintenance therapy.
The median duration of survival was 51 months and 46 months
respectively, P (2-sided) =0.59.




Age 0.459 0.875 0.782
Sex 0.999 0.686 0.916
Performance status 0.763 0.254 0.512
Haemoglobin 0.693 0.247 0.567
BUN 0.221 0.335 0.343
IgA/G 0.086a 0.278a 0.073a
Kappa/lambda 0.452 0.598 0.257
No. lytic bone lesions 0.395 0.685 0.673
Stage 0.347 0.192 0.559
Calcium 0.230 0.0010a 0.0066a
M-protein T 1/2 0.0050a 0.0038a <0.000la
% serum M-protein drop 0.0003a 0.0023a <0.000oa
aFactors in the Cox proportional hazards model.





Performance status 0.062 0.289
Haemoglobin 0.146 0.251
BUN 0.052 0.404
Ig light chain 0.119 0.618
No. lytic lesions 0.0684 0.792
Stage 0.0241 0.352
Calcium 0.0088 0.0076a
M-protein T 1/2 0.133 0.0041a
% Serum M-protein drop 0.0691 0.006a
aFactors in the Cox proportional hazards model.
Table V Halving time of serum M-





T 1/2 86 119a
Doubling time 138 75
Spearman correlation coefficient
0.28 P=0.0141.
aExcludes light chain cases (see
Methods).










No. lytic lesions 0.272
Stage 0.613
Heavy chain versus light chain only 0.22398 A. BELCH et al.
Table VII Influence of initial response pattern and symptoms at
relapse on chance of a second response in no maintenance arm
Second response P-value (two-sided)
Single
Yes No factor Multifactor
Median first remission
duration (days) 485 343 0.21 0.351
First remission
duration
<1 year 4628% 32% 0.041 0.166
Mean % serum
M-protein drop 79% 66% 0.004 0.027a
Median T 1/2 (days) 86 88 0.655 0.4287
Median doubling
time (days) 158 155 0.443 0.1253
Presence of symptoms
Yes 78% 26% <0.001 0.002a
aFactors in the model.
were present at relapse is also shown in Table VII. Sixty-
eight percent of those patients whose first remission was at
least one year achieved a second response compared to 42%
for those whose first remission was less than one year
(P=0.041, two-sided). Seventy-eight percent of those without
symptoms achieved a second response compared to 34% of
those with symptoms (P<0.001, two-sided).
In a multifactor logistic regression, the significance levels
for the effect on second response of first remission duration,
percentage drop in M-protein and presence of symptoms are
0.351, 0.027 and 0.002 respectively.
Discussion
Our current treatment for symptomatic multiple myeloma is
intended to produce an initial response with maximal
tumour regression usually followed by some type of
maintenance therapy (Bergsagel, 1985). However, the role of
maintenance therapy has never been shown to be beneficial,
and it is associated with modest risk and discomfort,
increased cost, and may contribute to an increased incidence
of acute leukaemia. The previous SWOG study showed no
decrease in remission duration or survival in responding
patients who stopped treatment after at least 12 months of
therapy but the study had a low power to detect a significant
difference because of its small sample size. The British
Medical Research Council Study, which enrolled many more
patients, also confirmed no significant difference in survival.
Time to first relapse and second response rates were not
reported. The entry criteria were different in that patients
had to stabilize on treatment for at least 6 months but not
necessarily respond. The majority, however, did have at least
a partial response. The study also differed from both the
SWOG study and this NCIC study in that treatment in the
maintenance arm was of only one year's duration following
randomization rather than until relapse. Despite the
differences in design of these two previous studies and this
NCIC study, our results confirm that there is no survival
difference when treatment is discontinued following disease
stabilization on initial chemotherapy. However we did
observe a statistically significant decrease in time to relapse
in the no maintenance group.
These two observations are compatible given that the
response rate to the reinstitution of MP at relapse in the no
maintenance group was high (57%). Clearly, when the
unmaintained patients eventually relapse, the malignant cells
which regrow frequently retain their sensitivity to initial
treatment. This then accounts for the fact that the time to
when melphalan is no longer of clinical value is similar in
both arms with an observed advantage to the unmaintained
arm. This also explains the similarity in the overall survival
experience between the two arms.
We are able to identify groups at high risk of early first
relapse and short survival but the prognosis of most of these
groups was similarly poor both in the maintained and
unmaintained arms. The presence of hypercalcemia, a short
T 1/2 and a relatively small reduction in M-protein were
significant predictors both of early relapse and short
survival. Increasing age was associated with a poorer
survival but not a shorter time to relapse. All of these
factors except serum calcium were predictive of poor
outcome in both treatment arms. Hypercalcemia was a
significant predictor of early relapse only in the no
maintenance group but it was associated with poor survival
in both groups with no significant survival benefit seen in
the maintenance group. Therefore, not only did dis-
continuing therapy not jeopardize the survival of the group
as a whole, we could not identify any subset of the group
that did have a survival advantage with maintenance
therapy. The fact that pattern of response to treatment is
highly significant in predicting the duration of response and
survival corroborates the observation that rapidly responding
patients actually have shorter survival (Hobbs, 1969).
The significant correlation between T 1/2 and serum M-
protein doubling time at relapse may explain the shortened
survival in these rapidly responding individuals. We hypo-
thesize that induction therapy kills rapidly proliferating
plasma cell tumours at a faster rate than slowly growing
tumours, resulting in a shorter T 1/2. The fact that T 1/2 and
doubling time strongly correlate suggests that the more rapid
plasma cell proliferative rate observed initially is retained at
relapse. Consequently, our induction chemotherapy has not
affected the kinetic biological determinants of this illness.
Our data suggest that responding patients with a high risk
of relapse are best identified after the serum M-protein T 1/2
and extent of maximal decrement is known. Such patients
would then be eligible for innovative maintenance therapy
programs.
It should be noted that our analysis of prognostic factors
predicting for relapse and survival has been done only for
the subgroup of patients who achieved a stable response to
MP. If the prognostic factors affecting the survival of all
myeloma patients were considered, it would not be surprising
if other factors such as stage and renal function emerged as
important variables.
The observation of an increased risk of developing acute
leukaemia in myeloma patients treated with alkylating agents
has been recently reviewed (Bergsagel, 1985). If we were able
to demonstrate a dose response relationship between the
total dose of melphalan and the incidence of acute leukaemia
then this would favour the hypothesis that the high risk of
developing leukaemia is therapy-related. The current
incidence of acute leukaemia in our study is similar in both
treatment groups. However, since the risk of developing
acute leukaemia increases with the duration of survival in
myeloma patients, these groups will require longer follow-up
to assess fully the influence of melphalan dose on the
incidence of acute leukaemia.
From this study we can conclude that maintenance MP
offers no survival advantage in patients who have had a
stable response to treatment and that treatment can safely be
stopped. While this conclusion is based on the analysis of
the whole group, we could also not identify any sub-group in
whom maintenance treatment conferred a survival benefit. It
should be stressed however, that our unmaintained patients
received regular medical follow-up with regular monitoring
of serum and urinary M-protein levels so that treatment
could be reinstituted promptly when necessary. The fact that
the likelihood of a second response to the reinstitution of
therapy was significantly less in symptomatic patients is of
concern since it suggests that these patients might have done
better if treatment had been restarted prior to theTREATMENT OF MULTIPLE MYELOMA 99
development of symptoms. We therefore recommend that, if
therapy is discontinued in responding patients, their M-
protein levels should be monitored closely and treatment
should be resumed at the first sign of relapse without
delaying until symptoms also recur.
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